

KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai –400002

Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad,
Gujarat-380006

Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com,

Website: www.kashyaptele-medicines.com

Date: 27th July, 2022

To,
BSE Limited
Listing Department
Phiroz Jeejeebhoy Tower,
25th Floor, Dalal Street,
Mumbai-400001

Scrip Code – 531960

Sub.: Submission of Unaudited Financial Results of the Company and Limited Review Report thereon as per regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the first quarter ended 30th June, 2022.

Dear Sir/Madam,

With reference to above mentioned subject and pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015, read with SEBI Circular no. CIR/CFD/FAC/62/2016 dated 5th July, 2016, SEBI Circular No. CIR/CFD/CMD1/44/2019 dated 29th March, 2019 and SEBI Circular No. CIR/CFD/CMD1/80/2019 dated 19th July, 2019; Unaudited Financial Results of the Company for the first quarter ended 30th June, 2022, as prepared in accordance with Schedule III of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015 (IND-AS), were duly reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at their respective meetings held on 27th July, 2022 and the copies of which along with Limited Review Report thereon as received from the Statutory Auditor of the Company are enclosed herewith.

Further, Limited Review Report of the said Unaudited Financial Results of the Company for the first quarter ended 30th June, 2022 is enclosed herewith in pursuance to Regulation 33 of SEBI (LODR) Regulations, 2015 as received from the Auditors of the Company.

Further, pursuant to Regulation 46 & 47 of SEBI (LODR) Regulations, 2015, the said result will be will be uploaded on the website of the Company and will be duly published in the required newspaper within prescribed timeframe.

Kindly take the above disclosures on your record as compliance with Regulation 33 of the SEBI (LODR) Regulations, 2015.

You are requested to take note of the same.

Thanking you.

Yours faithfully,

For, KASHYAP TELE-MEDICINES LIMITED




PARITOSH TRIVEDI
COMPANY SECRETARY

Encl: As above



SAREMAL & CO

Chartered Accountants

CA Saremal Shah (Bcom, FCA); CA Pravin Lavana (Bcom, LLB, FCA)

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON THE QUARTERLY UNAUDITED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30TH JUNE, 2022 OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, AS AMENDED

To
The Board of Directors,
KASHYAP TELE-MEDICINES LIMITED
AHMEDABAD

1. We have reviewed the accompanying statement of Un-audited Financial Results of **M/S KASHYAP TELE-MEDICINES LIMITED** (the Company) for the first quarter ended 30th June, 2022 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended (the 'Listing Regulations'), read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, SEBI Circular No. CIR/CFD/CMD1/44/2019 dated 29th March, 2019 and SEBI Circular No. CIR/CFD/CMD1/80/2019 dated 19th July, 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Statement on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our Conclusion is not modified in respect of this matter.



For SAREMAL & CO.
Chartered Accountants

Pravin Lavana
(Partner)

Membership NO.: 037180

Firm Registration NO.: 109281W

UDIN No. 22037180ANROOR4377

Ahmedabad, 27th July, 2022

KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai – 400002
 Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006
 Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com
 Website: www.kashyaptele-medicines.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30TH JUNE, 2022

(As per Regulation 33 of SEBI (LODR) Regulations, 2015 & Schedule III Companies Act, 2013 read with IND-AS)

S.No.	Particulars	Amount (Rs.) in Lakhs Except EPS			
		Quarter Ended			Year ended
		30/06/2022	31/03/2022	30/06/2021	31/03/2022
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I	Revenue from operations	5.30	4.00	5.00	19.55
II	Other Income	0.00	0.00	0.00	0.00
III	Total Revenue (I + II)	5.30	4.00	5.00	19.55
IV	Expenses				
	(a) Cost of materials consumed	0.00	0.00	0.00	0.00
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00
	(d) Employee benefits expense	2.55	2.30	2.21	9.27
	(e) Finance Cost	0.00	0.00	0.00	0.00
	(f) Depreciation and amortisation expense	0.00	0.00	0.00	0.00
	(g) Other expenses	1.98	14.85	1.89	20.69
	Total expenses	4.53	17.15	4.10	29.96
V	Profit/(Loss) before exceptional and extraordinary items and tax (III-IV)	0.77	(13.15)	0.90	(10.41)
VI	Exceptional items	0.00	(162.46)	0.00	(162.46)
VII	Profit before extraordinary items and tax (V - VI)	0.77	(175.61)	0.90	(172.87)
VIII	Extraordinary items	0.00	0.00	0.00	0.00
IX	Profit/(Loss) Before Tax (VII- VIII)	0.77	(175.61)	0.90	(172.87)
X	Tax expense :-				
	(a) Current tax	0.19	(0.63)	0.21	0.00
	(b) Tax relating to previous year	0.00	(0.11)	0.00	(0.11)
	(c) Deferred tax	0.00	0.00	0.00	0.00
	Total Tax Expense	0.19	(0.74)	0.21	(0.11)
XI	Profit / (Loss) for the period from continuing operations (IX - X)	0.58	(174.87)	0.69	(172.76)
XII	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00
XIII	Tax expense of discontinuing operations	0.00	0.00	0.00	0.00
XIV	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	0.00	0.00	0.00	0.00
XV	Profit / (Loss) for the period (XI + XIV)	0.58	(174.87)	0.69	(172.76)
XVI	Share of profit / (loss) of Associates	N.A.	N.A.	N.A.	N.A.
XVII	Minority interest	N.A.	N.A.	N.A.	N.A.
XVIII	Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates	0.58	(174.87)	0.69	(172.76)
XIX	Other Comprehensive Income				
	A. Items that will be/will not be reclassified to profit and loss	0.00	0.00	0.00	0.00
	B. Income tax relating to items that will be / will not be reclassified to profit and loss	0.00	0.00	0.00	0.00
XX	Total comprehensive income for the period (XVIII+XIX)	0.58	(174.87)	0.69	(172.76)
XXI	Paid-up equity share capital (Face Value of Rs. 1/- each)	477.22	477.22	477.22	477.22
XXII	Earnings per equity share:				
	(a) Basic	0.001	(0.366)	0.001	(0.362)
	(b) Diluted	0.001	(0.366)	0.001	(0.362)

- Notes:**
- The above Unaudited Financial Results of the company for the quarter ended on 30th June, 2022 have been reviewed by the Audit Committee and approved by the Board of Directors in the Meeting held on 27th July, 2022.
 - The Company has adopted, Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ('Ind As') from 1st April, 2017 and accordingly these financial results and all the periods presented have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting" read with relevant rules issued thereunder and the other accounting principles generally accepted in India and discloses the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 (as amended).
 - The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results for the quarter ended on 30th June, 2022 in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.
 - A Copy of the aforesaid financial results is also available on the website of BSE Limited (www.bseindia.com) and on the website of the Company (www.kashyaptele-medicines.com).
 - The company is engaged in single segment therefore has only one reportable segment in accordance with Ind AS 108 'Operating Segments'.
 - Figures pertaining to previous year/periods have been re-grouped and re-arranged wherever necessary.

Place : Ahmedabad
 Date : 27th July, 2022



For and on behalf of Board of Directors of
 Kashyap Tele - Medicines Limited



Amit Agarwal
 Managing Director
 DIN: 00159061